Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas To Develop Beta-Secretase Inhibitor For Alzheimer’s In Deal With CoMentis

This article was originally published in The Pink Sheet Daily

Executive Summary

$760 million gets Japanese pharma a Phase I compound and research into more potential disease modifying therapies for Alzheimer’s.

You may also be interested in...



Start-Up Archer Preps Alzheimer’s Drugs For Phase I

IND filed, company aims to use nilvadipine derivative against soluble amyloid.

Start-Up Archer Preps Alzheimer’s Drugs For Phase I

IND filed, company aims to use nilvadipine derivative against soluble amyloid.

Astellas Announces 32 Percent Earnings Increase For Fiscal 2007

Tokyo firm anticipates 10.4 percent drop in fiscal 2008 with Prograf patent expiry.

Related Content

Topics

UsernamePublicRestriction

Register

LL079488

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel